Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.69 |
| ▸ | TERT | O14746 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | POLH | Q9Y253 | 3/20 | 0.61 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypolaetin SCHEMBL7743466 | 1.00 | BCL2 (0.69) | BCL2TERTBRD4AKT1KDM4E | |
| Hypolaetin SCHEMBL29929121 | 1.00 | BCL2 (0.69) | BCL2TERTBRD4AKT1KDM4E | |
| Hypolaetin SCHEMBL29929136 | 1.00 | BCL2 (0.69) | BCL2TERTBRD4AKT1KDM4E | |
| SCHEMBL6614337 | 0.87 | KDM4E (0.62) | BCL2TERTBRD4AKT1KDM4E | |
| SCHEMBL31051320 | 0.87 | KDM4E (0.62) | BCL2TERTBRD4AKT1KDM4E | |
| SCHEMBL6801132 | 0.87 | TERT (0.64) | BCL2TERTBRD4KDM4EMEN1 | |
| SCHEMBL476215 | 0.86 | CBS (0.78) | TERTKDM4EMEN1MAPTALOX15 | |
| SCHEMBL28986431 | 0.86 | CBS (0.78) | TERTKDM4EMEN1MAPTALOX15 | |
| SCHEMBL29435853 | 0.86 | CBS (0.78) | TERTKDM4EMEN1MAPTALOX15 | |
| SCHEMBL12470189 | 0.86 | KDM4E (0.72) | BCL2TERTBRD4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-10 | — | — | US | disclosed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12453799-B1 | Bioadhesive for medical and dental applications | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-10-28 | — | — | US | disclosed |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-08-07 | — | — | US | disclosed |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-06-03 | — | — | US | disclosed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| US-11376570-B1 | Method of forming copper oxide-on-copper nanomaterial catalyst mesh | KING ABDULAZIZ UNIVERSITY (SA) | 2022-07-05 | — | — | US | disclosed |
| US-11364311-B2 | Method of identifying ASD phenotype 1 patients | Stalicla S.A. (CH) | 2022-06-21 | — | — | US | disclosed |
| US-11357871-B2 | Challenge test for diagnosing subtypes of ASD | Stalicla S.A. (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311492-B1 | Carbon nanomedicine with natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11234940-B1 | Method for making a noble metal nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | BCL2 646/4885TERT 2536/4885BRD4 2421/4885 |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | UGGT1, G6PD, UGT1A3 | BCL2 2046/4885TERT 917/4885BRD4 3094/4885 |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | SLC2A3, SLC2A1, SLC2A8 | BCL2 1200/4885TERT 1242/4885BRD4 4153/4885 |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | UGGT1, G6PD, UGDH | BCL2 2020/4885TERT 1621/4885BRD4 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.